FlucytosineCAS# 2022-85-7 |
- Cefditoren Pivoxil
Catalog No.:BCC4898
CAS No.:117467-28-4
- Cefoselis
Catalog No.:BCC4092
CAS No.:122841-10-5
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- Pefloxacin Mesylate Dihydrate
Catalog No.:BCC5089
CAS No.:149676-40-4
- Tinidazole
Catalog No.:BCC4866
CAS No.:19387-91-8
- Toltrazuril
Catalog No.:BCC4870
CAS No.:69004-03-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 2022-85-7 | SDF | Download SDF |
PubChem ID | 3366 | Appearance | Powder |
Formula | C4H4FN3O | M.Wt | 129.09 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | 5-Fluorocytosine; NSC 103805; Ro 2-9915 | ||
Solubility | DMSO : 16.67 mg/mL (129.13 mM; Need ultrasonic) H2O : 6.67 mg/mL (51.67 mM; Need ultrasonic) | ||
Chemical Name | 6-amino-5-fluoro-1H-pyrimidin-2-one | ||
SMILES | C1=NC(=O)NC(=C1F)N | ||
Standard InChIKey | XRECTZIEBJDKEO-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Flucytosine (5-Fluorocytosine, 5-FC, Ancobon), a fluorinated pyrimidine analogue, is an antifungal drug.
Target: antifungal
Flucytosine, or 5-fluorocytosine, a fluorinated pyrimidine analogue, is a synthetic antimycotic drug. It is structurally related to the cytostatic fluorouracil and to floxuridine. It is available in oral and in some countries also in injectable form. A common brand name is Ancobon. Flucytosine was first synthesized in 1957 but its antifungal properties were discovered in 1964. The drug is dispensed in capsules of 250 mg and 500 mg strength. The injectable form is diluted in 250 mL saline solution to contain 2.5 g total (10 mg/mL). The solution is physically incompatible with other drugs including amphotericin B.
Flucytosine is well absorbed (75 to 90%) from the gastrointestinal tract. Intake with meals slows the absorption, but does not decrease the amount absorbed. Following an oral dose of 2 grams peak serum levels are reached after approximately 6 hours. The time to peak level decreases with continued therapy. After 4 days peak levels are measured after 2 hours. The drug is eliminated renally. In normal patients flucytosine has reportedly a half-life of 2.5 to 6 hours. In patients with impaired renal function higher serum levels are seen and the drug tends to cumulate in these patients. The drug is mainly excreted unchanged in the urine (90% of an oral dose) and only traces are metabolized and excreted in the feces. Therapeutic serum levels range from 25 to 100 ?g/ml. Serum levels in excess of 100 ug are associated with a higher incidence of side effects. Periodic measurements of serum levels are recommended for all patients and are a must in patients with renal damage. References: |
Flucytosine Dilution Calculator
Flucytosine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 7.7465 mL | 38.7327 mL | 77.4653 mL | 154.9307 mL | 193.6633 mL |
5 mM | 1.5493 mL | 7.7465 mL | 15.4931 mL | 30.9861 mL | 38.7327 mL |
10 mM | 0.7747 mL | 3.8733 mL | 7.7465 mL | 15.4931 mL | 19.3663 mL |
50 mM | 0.1549 mL | 0.7747 mL | 1.5493 mL | 3.0986 mL | 3.8733 mL |
100 mM | 0.0775 mL | 0.3873 mL | 0.7747 mL | 1.5493 mL | 1.9366 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Flucytosine (5-Fluorocytosine, 5-FC, Ancobon), a fluorinated pyrimidine analogue, is an antifungal drug.
- Spiperone hydrochloride
Catalog No.:BCC6882
CAS No.:2022-29-9
- Bilastine
Catalog No.:BCC5263
CAS No.:202189-78-4
- Tenofovir Disoproxil Fumarate
Catalog No.:BCC1108
CAS No.:202138-50-9
- Kaempferol 7-O-rhamnoside
Catalog No.:BCN6489
CAS No.:20196-89-8
- LY341495
Catalog No.:BCC1724
CAS No.:201943-63-7
- Epicatechin pentaacetate
Catalog No.:BCN4884
CAS No.:20194-41-6
- PTAC oxalate
Catalog No.:BCC6217
CAS No.:201939-40-4
- Ombuoside
Catalog No.:BCN3711
CAS No.:20188-85-6
- Magnolioside
Catalog No.:BCN2832
CAS No.:20186-29-2
- Pisatin
Catalog No.:BCN3912
CAS No.:20186-22-5
- Tenuifolin
Catalog No.:BCN5005
CAS No.:20183-47-5
- Z-Leu-OH
Catalog No.:BCC2766
CAS No.:2018-66-8
- Spiraeoside
Catalog No.:BCC8251
CAS No.:20229-56-5
- Dregeoside Aa1
Catalog No.:BCN4678
CAS No.:20230-41-5
- Dasycarpol
Catalog No.:BCN7134
CAS No.:202343-57-5
- PNU-159682
Catalog No.:BCC5463
CAS No.:202350-68-3
- Scillascillol
Catalog No.:BCN7008
CAS No.:2023822-39-9
- Scillascillone
Catalog No.:BCN6992
CAS No.:2023822-40-2
- Scillascilloside B-1
Catalog No.:BCN6998
CAS No.:2023822-41-3
- 2,2-Bis(4-chloroformyloxyphenyl)propane
Catalog No.:BCC8491
CAS No.:2024-88-6
- Etoricoxib
Catalog No.:BCC1565
CAS No.:202409-33-4
- Hydroxygenkwanin
Catalog No.:BCN4885
CAS No.:20243-59-8
- 1,3,7-Trihydroxy-2-prenylxanthone
Catalog No.:BCN4886
CAS No.:20245-39-0
- AM 281
Catalog No.:BCC6944
CAS No.:202463-68-1
Flucytosine analogues obtained through Biginelli reaction as efficient combinative antifungal agents.[Pubmed:28189732]
Microb Pathog. 2017 Apr;105:57-62.
Invasive fungal infection is a problem that continues to challenge the healthcare sector. New antifungals and new therapeutic strategies are needed to address this challenge. We previously reported that the combination of a synthetic compound with a drug with known mechanism of action is a good strategy to treat aggressive and resistant fungi. Here we revisited our approach and synthesized structural analogues of Flucytosine, which is a synthetic antifungal and is being studied for its use in combination therapy with other antifungal drugs. Pyrimidin-one and -thione (often known as DHPM's) as Flucytosine analogues were obtained through a Biginelli reaction of corresponding aldehydes, ethylacetoacetate and urea/thiourea. Structure was confirmed by FTIR, (1)HNMR, (13)CNMR, COSY and MS (ESI(+)) analysis. All the newly synthesized derivatives were evaluated for the antifungal activity alone and in combination of two most commonly used antifungal drugs, amphotericin B and fluconazole against different clinically isolated Candida albicans strains. Minimum inhibitory concentration results confirmed that BG4 possess high antifungal activity against all the tested strains (MIC = 1-32 mug/ml). For all the combinations with amphotericin B and fluconazole, 37% were synergistic followed by 30% additive and 24% indifferent interactions. Interestingly, 9% antagonistic interaction was observed when BG1 and BG3 were combined with fluconazole, however, no antagonistic interaction was observed with amphotericin B. In-depth studies of all the synergies were done by constructing isobolograms with nine different ratio combinations. These results warrant the use of DHPM derivatives as chemosensitising agents which could lower down the dosages of the antifungal drugs to treat invasive fungal diseases.
Vertical-flow paper SERS system for therapeutic drug monitoring of flucytosine in serum.[Pubmed:27876146]
Anal Chim Acta. 2017 Jan 1;949:59-66.
A number of life-saving drugs require therapeutic drug monitoring (TDM) for safe and effective use. Currently, however, TDM is performed using sophisticated analytical techniques relegated to central labs, increasing the cost per test and time to answer. Here, using a novel vertical flow membrane system with inkjet-printed surface enhanced Raman sensors, along with a portable spectrometer, we demonstrate a low cost and easy to use device to quantify levels of Flucytosine, an antifungal that requires TDM for effective patient care, from undiluted human serum. To our knowledge, this work represents the first report of a passive vertical flow sample cleanup method with surface enhanced Raman detection. We first investigated and optimized the parameters of the vertical flow system for the detection of Flucytosine in spiked serum samples. Then, using an optimized vertical-flow system utilizing nitrocellulose membranes and a paper SERS sensor, we achieved detection of down to 10 mug mL(-1) Flucytosine in undiluted serum, with quantitative detection across the entire therapeutic range. This system reduces the assay time to about 15 min, far quicker than the current gold standards. We anticipate that this novel system will enable near-patient therapeutic drug monitoring, leading to the safe and effective administration of a number of life-saving drugs. Furthermore, it will spawn the development of SERS detection systems capable of separating target analytes from real-world biological matrices.
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine.[Pubmed:28177438]
Ann Oncol. 2017 Jan 1;28(1):169-174.
Background: TG4023 is a modified vaccinia virus Ankara (MVA) containing the yeast-originated transgene FCU1, expressing cytosine deaminase and uracil phosphoribosyltransferase enzymes that transform the prodrug Flucytosine (5-FC) into cytotoxic 5-fluorouracil (5-FU) and 5-fluorouridine-5'-monophosphate, respectively. This first-in-human study aimed to assess the maximum tolerated dose (MTD) of intratumoral (IT) TG4023 and the safety, feasibility, and proof-of-concept (PoC) of TG4023/5-FC combination to deliver high 5-FU concentrations in tumors. Patients and Methods: Cancer patients without further therapeutic option and with at least one injectable primary or metastatic liver tumor underwent on day 1 a percutaneous IT injection of TG4023 at doses of 107, 108, or 4.108 plaque forming units (p.f.u.) using ultrasound imaging guidance, after a dose-limiting toxicities (DLTs)-driven 3 + 3 dose-escalating design. On day 2, patients were given intravenous and/or oral 5-FC at a dose of 200 mg/kg/day for 14 days and were followed for safety through day 43. Tumor response was assessed at week 6, according to RECIST. Plasma and tumor 5-FU concentrations were measured to establish the PoC. Results: In total, 16 patients completed treatment with TG4023 and 5-FC. One DLT/7 patients (ALT/aspartate aminotransferase transient increase) was observed at 4 x 108 p.f.u.; MTD was therefore not reached. The most frequent adverse events were pyrexia, asthenia, vomiting, and decreased appetite. Eight of 16 patients had stable disease. Mean 5-FU concentrations in plasma were 1.9 +/- 2.6 ng/ml and 56 +/- 30 ng/g in tumors. Seroconversion for anti-FCU1 antibodies was found for one patient from each cohort (16%, overall). Conclusions: This phase I study demonstrated that IT injections of TG4023 were feasible and well tolerated; MTD was defined as 4 x 108 p.f.u. Therapeutic 5-FU concentrations in tumors established the virus-directed enzyme-prodrug therapy PoC. Clinicaltrials.gov Number: NCT00978107.
Membrane Proteomics Analysis of the Candida glabrata Response to 5-Flucytosine: Unveiling the Role and Regulation of the Drug Efflux Transporters CgFlr1 and CgFlr2.[Pubmed:28066366]
Front Microbiol. 2016 Dec 21;7:2045.
Resistance to 5-Flucytosine (5-FC), used as an antifungal drug in combination therapy, compromises its therapeutic action. In this work, the response of the human pathogen Candida glabrata to 5-FC was evaluated at the membrane proteome level, using an iTRAQ-based approach. A total of 32 proteins were found to display significant expression changes in the membrane fraction of cells upon exposure to 5-FC, 50% of which under the control of CgPdr1, the major regulator of azole drug resistance. These proteins cluster into functional groups associated to cell wall assembly, lipid metabolism, amino acid/nucleotide metabolism, ribosome components and translation machinery, mitochondrial function, glucose metabolism, and multidrug resistance transport. Given the obtained indications, the function of the drug:H+ antiporters CgFlr1 (ORF CAGL0H06017g) and CgFlr2 (ORF CAGL0H06039g) was evaluated. The expression of both proteins, localized to the plasma membrane, was found to confer Flucytosine resistance. CgFlr2 further confers azole drug resistance. The deletion of CgFLR1 or CgFLR2 was seen to increase the intracellular accumulation of 5-FC, or 5-FC and clotrimazole, suggesting that these transporters play direct roles in drug extrusion. The expression of CgFLR1 and CgFLR2 was found to be controlled by the transcription factors CgPdr1 and CgYap1, major regulator of oxidative stress resistance.